

## YOU ARE INVITED TO JOIN US

for a contemporary and clinically relevant educational activity which has been specifically designed to address the most frequently encountered clinical challenges in the management of patients with Atrial Fibrillation and the related co-morbidities in the primary care setting. This activity was developed by leading Canadian Experts to provide clinicians with answers to frequently asked questions and key take-away messages that can be applied to real-world practice.

### Join us for a group learning session

**Date:** December-10-2019

**Location:** location name 117 silver linden dr richmond hill ON

**Program Start Time:** 17:31 **Program End Time:** 18:31

**Speaker(s):** Dr. admin speaker **Moderator:** Dr. andrew lai  
Dr. GraceSpeaker  
LiSpeaker

**Registration / Meal Comments:** 17:31 Meal Start Time:17:31

### RSVP:

ModeratorTest ModeratorLast alai2@outlook.com 123

### Agenda & Learning Objectives

#### LEARNING OBJECTIVES: Clinical Conundrums IV - 2019 Update

##### After participating in this activity, I am now better able to:

1. Select personalized treatment options for stroke prevention in atrial fibrillation using current Canadian Practice Guidelines supplemente with reassuring "Real World" experience
2. Assess and optimize bleeding risk of atrial fibrillation patients requiring long-term DOAC stroke prevention treatment.
3. Recognize the current treatment gap in Canada and take steps at ensuring appropriate dosage selection and long-term compliance with oral anticoagulation among AF patients

#### LEARNING OBJECTIVES: Case 2: Management of Atrial Fibrillation with Gastrointestinal Complications

##### After participating in this activity, I am now better able to:

1. Implement best evidence and guidelines in the management of patients with GI bleeding and AF
2. Assess when it is safe to resume oral anticoagulation in patients with AF and GI bleed
3. Evaluate and differentiate the evidence of individual DOACs on risk of GI bleeding in patients with AF
4. Assess the potential role of PPIs to reduce the risk of a GI bleed
5. Determine the clinical settings where the addition of ASA to a DOAC or to warfarin is worth the added bleeding risk

This Group Learning program has been reviewed by the College of Family Physicians of Canada and is awaiting final certification by the College's Ontario Chapter

This program has received an educational grant and in-kind support from BMS/Pfizer Alliance Canada

